| dc.contributor | 心理系 | |
| dc.creator (作者) | Wu, P.-L.;Tang, Hwa-Sheng;Lane, H.-Y.;Tsai, C.-A.;Tsai, G.E. | |
| dc.creator (作者) | 湯華盛 | zh_TW |
| dc.date (日期) | 2011-06 | |
| dc.date.accessioned | 18-May-2015 17:35:19 (UTC+8) | - |
| dc.date.available | 18-May-2015 17:35:19 (UTC+8) | - |
| dc.date.issued (上傳時間) | 18-May-2015 17:35:19 (UTC+8) | - |
| dc.identifier.uri (URI) | http://nccur.lib.nccu.edu.tw/handle/140.119/75175 | - |
| dc.description.abstract (摘要) | Background: Several lines of evidence implicate glutamatergic neurotransmission in the pathophysiology of obsessive compulsive disorder (OCD). Sarcosine is an endogenous antagonist of glycine transporter-1. By blocking glycine uptake, sarcosine may increase the availability of synaptic glycine and enhance N-methyl-d-aspartate (NMDA) subtype glutamatergic neurotransmission. In this 10-week open-label trial, we examined the potential benefit of sarcosine treatment in OCD patients. Method: Twenty-six outpatients with OCD and baseline Yale-Brown Obsessive Compulsive Scale (YBOCS) scores higher than 16 were enrolled. Drug-naive subjects (group 1, n = 8) and those who had discontinued serotonin reuptake inhibitors for at least 8 weeks at study entry (group 2, n = 6) received sarcosine monotherapy. The other subjects (group 3, n = 12) received sarcosine as adjunctive treatment. A flexible dosage schedule of sarcosine 500 to 2000 mg/d was applied. The primary outcome measures were Y-BOCS and Hamilton Anxiety Inventory, rated at weeks 0, 2, 4, 6, 8, and 10. Results were analyzed by repeated-measures analysis of variance. Results: Data of 25 subjects were eligible for analysis. The mean ± SD Y-BOCS scores decreased from 27.6 ± 5.8 to 22.7 ± 8.7, indicating a mean decrease of 19.8% ± 21.7% (P = 0.0035). Eight (32%) subjects were regarded as responders with greater than 35% reduction of Y-BOCS scores. Five of the responders achieved the good response early by week 4. Although not statistically significant, drug-naive (group 1) subjects had more profound and sustained improvement and more responders than the subjects who had received treatment before (groups 2 and 3). Sarcosine was tolerated well; only one subject withdrew owing to transient headache. Conclusion: Sarcosine treatment can achieve a fast therapeutic effect in some OCD patients, particularly those who are treatment naive. The study supports the glycine transporter-1 as a novel target for developing new OCD treatment. Large-series placebo-controlled, double-blind studies are recommended. © 2011 Lippincott Williams & Wilkins. | |
| dc.format.extent | 191563 bytes | - |
| dc.format.mimetype | application/pdf | - |
| dc.relation (關聯) | Journal of Clinical Psychopharmacology, 31(3), 369-374 | |
| dc.subject (關鍵詞) | alprazolam; amitriptyline; citalopram; clomipramine; clonazepam; escitalopram; fluoxetine; fluvoxamine; haloperidol; imipramine; olanzapine; paroxetine; risperidone; sarcosine; serotonin uptake inhibitor; sertraline; valproic acid; venlafaxine; zotepine; adult; article; clinical article; drug response; drug tolerability; drug withdrawal; dysthymia; female; headache; human; major depression; male; monotherapy; obsessive compulsive disorder; open study; priority journal; prospective study; Adult; Drug Therapy, Combination; Female; Glycine Plasma Membrane Transport Proteins; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Psychiatric Status Rating Scales; Psychotropic Drugs; Sarcosine | |
| dc.title (題名) | Sarcosine therapy for obsessive compulsive disorder: A prospective, open-label study | |
| dc.type (資料類型) | article | en |
| dc.identifier.doi (DOI) | 10.1097/JCP.0b013e3182189878 | |
| dc.doi.uri (DOI) | http://dx.doi.org/10.1097/JCP.0b013e3182189878 | |
